Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

Introduction: Pembrolizumab plus chemotherapy significantly improved survival outcomes versus placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC in the randomized, double-blind, phase 3 KEYNOTE-407 study. We present the results of Chinese patients enrolled in t...

Full description

Bibliographic Details
Main Authors: Ying Cheng, MD, Li Zhang, MD, Jie Hu, MD, PhD, FCCP, Donglin Wang, MD, ChengPing Hu, MD, Jianying Zhou, MD, Lin Wu, MD, Lejie Cao, MD, Jiwei Liu, MD, Helong Zhang, MD, Hong Sun, MD, Ziping Wang, PhD, Hongjun Gao, MD, Yuping Sun, MD, Ben Li, PhD, Xiaohan Hu, PhD, MPH, Paul Schwarzenberger, MD, Luis Paz-Ares, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:JTO Clinical and Research Reports
Subjects:
Programmed death 1 blockade
Pembrolizumab
Chemotherapy
Squamous Non–small-cell lung cancer
China
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000849

Similar Items

Similar Items